Expert Interview
Checking In With a Prescriber of Ardelyx’s XPHOZAH (tenapanor) as a Treatment for Hyperphosphatemia in Patients with Chronic Kidney Disease
Ticker(s): ARDXInstitution: Yale
- Clinical Professor of Medicine, Yale University & Section Chief of Nephrology at the Hospital of St. Raphael.
- Manages large CKD dialysis population treating many patients with iron deficiency.
- Speaker at many international Nephrology conferences.
Please describe your clinical practice; how many patients do you currently treat with CKD, what percent of your patients are on dialysis and what are the treatment options? How often do patients develop hyperphosphatemia?
What are the pros and cons of phosphate binders? Have the traditional issues of large pill size, objectionable taste, and multiple pills required for each meal and snack make phosphate been resolved ? What would you like to see in this space as an improvement?
Have any of your patients experienced gastrointestinal AEs on tenapanor? Any to the extent that it lead to treatment discontinuation?
What percentage of your dialysis patients are you prescribing XPHOZAH for?
Do you view greater utility for XPHOZAH in lowering pill burden in combination with phosphate binders or more as a monotherapy for those who are intolerant?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
